On Monday, Shares of Procter & Gamble Co (NYSE:PG), gained 1.05% to $78.95.
The People’s Choice Awards and CBS declared that Abigail Spencer, Adam Devine, Amber Valletta, Betsy Brandt, Britney Spears, Cheyenne Jackson, Chris D’Elia, Christina Milian, Clark Gregg, Colin Hanks, Connor Franta, Dakota Johnson, Ed Westwick, Gina Rodriguez, Jack Black, John Stamos, Josh Holloway, Kate Hudson, Kunal Nayyar, Lea Michele, Maddie Ziegler, Marcia Gay Harden, Mayim Bialik, Meagan Good, Meghan Trainor, Melissa Benoist, Melissa Rauch, Mike Epps, Ming-Na Wen, Nia Long, Natalie Dormer, Priyanka Chopra, Raza Jaffrey, Taylor Kinney, Vin Diesel and the Pink Ladies of “Grease: Live” (Carly Rae Jepsen, Julianne Hough, Keke Palmer, Kether Donohue and Vanessa Hudgens) will attend the 2016 awards show, live from the Microsoft Theater in Los Angeles, Wednesday, January 6, 2016, on the CBS Television Network (9:00-11:00 PM, ET/delayed PT).
Talent joins Shawn Mendes and Jason Derulo, who were formerly declared as performers at the 2016 show, and host Jane Lynch. The People’s Choice Awards are the only major awards show where fans determine the nominees and winners across categories of movies, music, television and digital.
The Procter & Gamble Company, together with its auxiliaries, manufactures and sells branded consumer packaged products worldwide. It operates through five segments: Beauty, Hair and Personal Care; Grooming; Health Care; Fabric Care and Home Care; and Baby, Feminine and Family Care.
Shares of Alibaba Group Holding Ltd (NYSE:BABA), inclined 0.27% to $82.87, during its last trading session.
Alibaba Group Holding Limited, declared the appointment of Matthew Bassiur as Vice President, Head of Global Intellectual Property Enforcement, effective January 2016.
In this new role, Mr. Bassiur will lead a team that works with international brands and retail partners, industry associations, government regulators, law enforcement and other organizations to advance Alibaba Group’s anti-counterfeiting and IP rights protection efforts. He will report to Michael Evans, President of Alibaba Group.
“Matthew’s appointment is the latest step in Alibaba Group’s comprehensive and industry-leading efforts to fight counterfeits,” said Jack Ma, Executive Chairman of Alibaba Group. “Counterfeiting is a problem that challenges all forms of distribution, whether in e-commerce or offline retail. We will continue to be relentless in our long-term commitment to protect both consumers and intellectual property rights owners, and we call on all companies in our industry to join our fight against bad actors.”
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally. It operates Taobao Marketplace, an online shopping destination; Tmall, a third-party platform for brands and retailers; Juhuasuan, a group buying marketplace; Alibaba.com, an online wholesale marketplace; Alitrip, an online travel booking platform; 1688.com, an online wholesale marketplace; and AliExpress, a consumer marketplace.
Finally, Gilead Sciences, Inc. (NASDAQ:GILD), ended its last trade with 1.01% gain, and closed at $102.63.
Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences, Inc. (GILD), declared that the companies have reached a global partnership for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory indications. Galapagos will receive an upfront payment of $725 million comprising of a license fee of $300 million and a $425 million equity investment in Galapagos. In addition, Galapagos is eligible for payments of up to $1.35 billion in milestones, with tiered royalties starting at 20% and a profit split in co-promotion territories.
Phase 2 trial data show that filgotinib has the potential to be an effective and well-tolerated oral therapy for patients with rheumatoid arthritis (DARWIN studies) and Crohn`s disease (FITZROY study). The companies will start Phase 3 trials in RA and Crohn`s in 2016 pending the successful outcome of negotiations with regulatory authorities.
“We are excited about the potential of filgotinib in RA and other diseases with a strong partner like Gilead, which shares our aim of rapidly delivering these therapies to patients,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “Furthermore, we look forward to the perspective of working together worldwide across other possible indications. The co-development and co-promotion aspects of this partnership bring us into the next phase of the company`s evolution.”
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
